Table 2.
Anatomic origin and microbiologic findings of S. maltophilia bacteremia in study participants
| Factors | Survivors N = 44 | Non-survivors N = 82 | p value |
|---|---|---|---|
| Infection source | |||
| Pneumonia | 12 (27.9) | 23 (28.0) | 0.987 |
| Catheter-related infection | 15 (34.1) | 34 (42.0) | 0.202 |
| Intra-abdominal infection | 16 (36.4) | 22 (27.2) | 0.285 |
| Soft tissue infection | 0 (0.0) | 5 (6.2) | 0.161 |
| Urinary tract infection | 1 (2.3) | 0 (0.0) | 0.352 |
| Polymicrobial infection | 18 (40.9) | 36 (43.9) | 0.746 |
| Antibiotics susceptibility | |||
| Quinolone resistance | 5 (11.6) | 34 (41.5) | 0.001 |
| TMP-SMX resistance | 3 (6.8) | 12 (14.6) | 0.197 |
| Resistant straina | 17 (38.6) | 49 (59.8) | 0.024 |
| Treatment | |||
| Empirical antibiotic use | |||
| Cephalosporins | 2 (4.5) | 6 (7.4) | 0.711 |
| Carbapenems | 13 (29.5) | 42 (51.9) | 0.016 |
| Fluoroquinolones | 13 (29.5) | 8 (9.8) | 0.004 |
| BLBLIs | 14 (31.8) | 16 (19.5) | 0.122 |
| TMP-SMX | 0 (0.0) | 0 (0.0) | – |
| Definitive antibiotic use | |||
| Carbapenems | 2 (4.5) | 16 (19.5) | 0.022 |
| Fluoroquinolones | 21 (47.7) | 19 (23.5) | 0.005 |
| BLBLIs | 3 (6.8) | 5 (6.2) | 1.000 |
| TMP-SMX | 4 (9.1) | 27 (33.3) | 0.003 |
| Inappropriate antimicrobial therapyb, yes | 14 (31.8) | 25 (30.9) | 0.912 |
Note. BLBLIs Beta-lactam/beta-lactamase inhibitors, TMP-SMX Trimethoprim-sulfamethoxazole
The data were expressed as number (%) or median (interquartile range)
aResistant strain, Quinolone or/and TMP-SMX resistance
bAppropriate antimicrobial therapy, the administration of at least one agent to which the index SM isolate was susceptible in vitro